- Home
- PAX vs NVAX Comparison
PAX vs NVAX Comparison
Compare PAX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAX
- NVAX
- Stock Information
- Founded
- PAX 1988
- NVAX 1987
- Country
- PAX Cayman Islands
- NVAX United States
- Employees
- PAX N/A
- NVAX N/A
- Industry
- PAX Investment Managers
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAX Finance
- NVAX Health Care
- Exchange
- PAX Nasdaq
- NVAX Nasdaq
- Market Cap
- PAX 1.8B
- NVAX 2.0B
- IPO Year
- PAX 2021
- NVAX 1995
- Fundamental
- Price
- PAX $11.65
- NVAX $8.40
- Analyst Decision
- PAX Strong Buy
- NVAX Buy
- Analyst Count
- PAX 1
- NVAX 6
- Target Price
- PAX $14.00
- NVAX $17.83
- AVG Volume (30 Days)
- PAX 590.4K
- NVAX 4.5M
- Earning Date
- PAX 02-13-2025
- NVAX 02-26-2025
- Dividend Yield
- PAX 5.15%
- NVAX N/A
- EPS Growth
- PAX N/A
- NVAX N/A
- EPS
- PAX 0.42
- NVAX N/A
- Revenue
- PAX $328,717,000.00
- NVAX $885,193,000.00
- Revenue This Year
- PAX $2.35
- NVAX N/A
- Revenue Next Year
- PAX $26.31
- NVAX N/A
- P/E Ratio
- PAX $27.62
- NVAX N/A
- Revenue Growth
- PAX 7.39
- NVAX N/A
- 52 Week Low
- PAX $10.63
- NVAX $3.53
- 52 Week High
- PAX $16.16
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- PAX 50.49
- NVAX 44.80
- Support Level
- PAX $11.10
- NVAX $8.35
- Resistance Level
- PAX $11.62
- NVAX $9.14
- Average True Range (ATR)
- PAX 0.30
- NVAX 0.64
- MACD
- PAX 0.01
- NVAX -0.06
- Stochastic Oscillator
- PAX 74.36
- NVAX 19.85
About PAX Patria Investments Limited
Patria Investments Ltd is a private markets investment firm. It seeks to provide global and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.